- Home
- GBR vs RDHL Comparison
GBR vs RDHL Comparison
Compare GBR & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBR | RDHL |
|---|---|---|
| Founded | 1978 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 3.7M |
| IPO Year | 1995 | 2012 |
Fundamental Metrics
Financial Performance| Metric | GBR | RDHL |
|---|---|---|
| Price | $0.58 | $0.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.4K | ★ 88.4K |
| Earning Date | 11-12-2026 | 09-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $155,000.00 | N/A |
| Revenue This Year | N/A | $17,592.31 |
| Revenue Next Year | N/A | $25.89 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.16 | N/A |
| 52 Week Low | $0.55 | $0.36 |
| 52 Week High | $1.31 | $1.60 |
Technical Indicators
Market Signals| Indicator | GBR | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 31.15 | 38.36 |
| Support Level | N/A | $0.38 |
| Resistance Level | $0.83 | $0.47 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 10.90 | 19.89 |
Price Performance
Historical ComparisonAbout GBR New Concept Energy Inc
New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.